Victoria Advisory Committee for Proton Therapy Launched at ASTRO 2018

October 29, 2018 — At the 2018 American Society for Radiation Oncology (ASTRO) annual meeting, IBA announced the launch of the Victoria Advisory Committee, a consortium of worldwide radiation therapy experts to help define the future of proton therapy care.

The clinical community and IBA are joining forces to push the boundaries of proton therapy even further and treat all patients that could benefit from it. The Victoria Advisory Committee consists of clinical experts from the world’s leading cancer centers specializing in radiation and proton therapy and includes:

• Jürgen Debus, M.D., Ph.D., Heidelberg University Hospital;
• Tom Depuydt, Ph.D., ParTICle/UZ Leuven;
• Adam Dicker, M.D., Ph.D., Jefferson University Hospitals;
• Peyman Kabolizadeh, M.D., Ph.D., Beaumont Health Proton Therapy Center;
• Zuofeng Li, D.Sc., University of Florida Health Proton Therapy Institute;
• Carlos Vargas, M.D., Mayo Clinic Arizona, and other experts from prestigious institutions such as the University of Pennsylvania.

The clinical experts will help define future roadmaps as well as help to make clinical adoption easy for technologies such as:

• Editable workflow — establishing a workflow framework to increase the treatment efficiency while navigating the growing treatment complexity;
• Arc Therapy- — introducing rotational arc proton therapy as an additional treatment option; and
• Adaptive technology — making online adaptive therapy a reality for proton therapy.
   

The first meeting of the Victoria Advisory Committee took place around the time of ASTRO 2018.

Kabolizadeh, medical director, Beaumont Health Proton Therapy Center, said, “We have recently announced the first irradiation of a Spot Scanning Proton Arc Therapy plan in our facility in Royal Oak, Mich., and we were excited to share the very promising initial results with the leading experts in the field during that meeting.”

Li, physics director, University of Florida Health Proton Therapy Institute (UFHPTI), stated: “As one of the pioneers in proton therapy with over 7,700 patients treated, we are delighted to contribute with our longstanding experience to advance proton therapy to the next level focusing on better treatment quality, reliability and efficiency.”

For more information: www.iba-worldwide.com